Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73684 | 0.90 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6898759 | 0.88 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL584864 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3838335 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL585308 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL584177 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL585171 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL7660482 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL302264 | 0.88 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL867361 | 0.86 | CA2 (0.39) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115602925-A | Electrolyte and battery comprising same | 珠海冠宇电池股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20210159541-A1 | ELECTROLYTE FOR LITHIUM BATTERY AND LITHIUM BATTERY COMPRISING SAME | SAMSUNG SDI CO., LTD. (KR) | 2021-05-27 | — | — | US | claimed |
| CN-110870126-A | Electrolyte for lithium battery and lithium battery including the same | 三星SDI株式会社 | 2020-03-06 | — | — | CN | claimed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | claimed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | claimed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | claimed |
| US-20010031891-A1 | Process for producing perfluoroalkanesulfinate | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-10-18 | — | — | US | claimed |
| EP-3351548-B1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-3824325-B1 | VEHICLE SENSORS COMPRISING REPELLENT SURFACE, PROTECTIVE FILMS, REPELLENT COATING COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-112470320-B | Nonaqueous electrolyte for battery and lithium secondary battery | 三井化学株式会社 | 2024-12-27 | — | — | CN | disclosed |
| US-12095037-B2 | Non-aqueous electrolyte solution for battery and lithium secondary battery | MITSUI CHEMICALS, INC. (JP) | 2024-09-17 | — | — | US | disclosed |
| CN-118412540-A | Nonaqueous electrolyte for battery and lithium secondary battery | 三井化学株式会社 | 2024-07-30 | — | — | CN | disclosed |
| US-12032288-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2024-07-09 | — | — | US | disclosed |
| WO-1999058745-A1 | ELECTROCHEMICAL FLUORINATION OF ALKANE SUBSTRATE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0643155-B1 | Process for preparing fluorochemicals | MINNESOTA MINING & MFG (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0690147-B1 | Process for the electrochemical fluorination of a hydrocarbon substratum | HALDOR TOPSOE AS (DK) | 1998-01-07 | — | — | EP | disclosed |
| US-5575906-A | Process for the electrochemical fluorination of a hydrocarbon substrate | Haldor Tops.o slashed.e A/S (DK) | 1996-11-19 | — | — | US | disclosed |
| EP-0690147-A1 | Process for the electrochemical fluorination of a hydrocarbon substratum | Haldor Topsoe A/S (DK) | 1996-01-03 | — | — | EP | disclosed |
| EP-0643155-A2 | Process for preparing fluorochemicals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5387323-A | Process for preparing fluorochemicals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CA2 4346/4885CA1 4130/4885MMP1 3339/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CA2 4346/4885CA1 4130/4885MMP1 3339/4885 |
| US-12032288-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, and method for manufacturing electronic device | RER1, COL1A1, RAD51 | CA2 4690/4885CA1 3086/4885MMP1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.